You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥(1672.HK)高開44.58% 泰國發現有效治療新冠肺炎的用藥方案涉及利托那韋
格隆匯 02-03 09:25
格隆匯2月3日丨歌禮制藥(1672.HK)高開44.58%報6港元,盤前成交830.4萬港元,最新總市值66.38億港元。泰國衞生部昨日稱:泰國發現有效治療新冠肺炎的用藥方案,使用後48小時檢測結果轉為陰性。據悉,該藥方通過使用政府醫用組織生產的治療艾滋病的藥物(洛匹那韋/利托那韋),並輔以治療流感的藥物(奧司他韋)研製得出。注:利托那韋(Ritonavir)及ASC09複方片(活性成分為ASC09 和利托那韋)均為歌禮制藥尚未獲得上市批文的產品。另外,主產奧司他韋的東陽光藥(1558.HK)高開2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account